[Filler-controlled release from suspension matrices (laminates)].

B C Lippold; P Kurka

Home/Archive/PubMed

PubMed · 3438337

[Filler-controlled release from suspension matrices (laminates)].

B C Lippold·P Kurka

View original source ↗Export metadata ↓

Abstract

The release from a matrix (polyethylenmineral oilgel, Plastibase) with drug (bupranolol) in suspension can be controlled by a controlling layer of the same material which is saturated with the drug. Thus, after a burst period zero order release is reached from the laminate, before square root t-kinetics predominate. The duration of constant release may be extended with fillers in the controlling layer (glass beads, d less than 20 microns). Increasing the thickness of the controlling layer increases both duration of constant release and time to reach it, the latter to a lower extent.

Explore related subjects

Bupranolol Chemistry, Pharmaceutical Delayed-Action Preparations Excipients Suspensions Time Factors English Abstract Journal Article Research Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

B C Lippold, P Kurka. 1987. [Filler-controlled release from suspension matrices (laminates)].. https://pubmed.ncbi.nlm.nih.gov/3438337/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1986

Interactions of vasodilators with calcium entry- and beta-blockers in patients with coronary heart disease.

Combinations of antianginal drugs may be used for an additive effect against angina, but also to off-set unwanted effects of one drug with another, either by direct effects or by a reduction of dosage of each drug. Based on earlier studies with separate drugs we have now examined the effect of 150 mg bupranolol combined with 40 mg isosorbide dinitrate (ISDN) in one retarded tablet, given twice daily. 22 patients with CHD entered the study, 11 of those with and 11 without signs of ischemia during exercise. In an acute radionuclide ventriculographic (RNV) study 2 h after the tablet, ejection fraction (EF) during exercise increased only in patients with exercise ischemia (+6%, p less than 0.001). In the other patients EF did not change. After 21 days of treatment echocardiographically determined end-systolic and end-diastolic diameters decreased, resulting in an increase of shortening fraction by 15.6% (p less than 0.05). Heart rate, systolic and diastolic pressure and ST-segment depression decreased significantly. In another acute RNV study the effect of a venous vasodilator, molsidomine 4 mg s.l., was examined after nifedipine 10 mg s.l. in 19 patients with CHD, 9 with and 10 without exercise ischemia. Differences between drugs were most prominent during exercise. In the nonischemic group EF rose by 6.6% after nifedipine (n.s.) and by 14% after molsidomine (p less than 0.01 against control). In the group with ischemia EF rose by 12.6% after nifedipine and by 17.4% after additional molsidomine, significant against control (p less than 0.01) as well as against nifedipine (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Bupranolol↗

PubMed1985

Phase behaviour of a diglyceride prodrug: spontaneous formation of unilamellar vesicles.

A prodrug (Fig. 1(IV)) is synthesized consisting of the beta-blocker bupranolol which is covalently linked to 1, 3-dipalmitoyl-2-succinyl-glycerol. The resulting lipid-like prodrug is amphipathic and surface active. It disperses readily in H2O above 30 degrees C forming a smectic lamellar phase. This prodrug bears one positive charge at neutral pH and hence the swelling behaviour of dispersions in H2O is similar to that of charged phospholipids: the dispersions show continuous swelling with increasing water content and consequently in the excess H2O region of the phase diagram the thermodynamically most stable structure is the unilamellar vesicle. This includes oligomeric vesicles which may be defined as unilamellar vesicles containing smaller, also unilamellar vesicles entrapped in their internal aqueous compartment. The prodrug dispersions in H2O are polydisperse with vesicle sizes ranging from 0.1 micron to several micron. Sonication of these dispersions produce small unilamellar vesicles of an average size and size distribution similar to sonicated egg phosphatidylcholine dispersions. Unsonicated dispersions of the prodrug in H2O undergo reversibly sharp order-disorder transitions at 32 degrees C with an enthalpy change of delta H = 10 kcal/mol. In sonicated aqueous dispersions this phase transition is asymmetric and significantly broadened indicating that the cooperativity is markedly reduced. The peak temperature and enthalpy change of this broad transition are reduced compared to the transition observed with unsonicated dispersions. The temperature dependence of the electron spin resonance (ESR) hyperfine splitting and order parameter also reflects the order-disorder transition. From ESR spin labeling it is concluded that in sonicated dispersions the prodrug molecule is more mobile and its anisotropy of motion is reduced compared to unsonicated dispersions. This result indicates that the molecular packing in the highly curved bilayers of small unilamellar prodrug vesicles is significantly perturbed compared to bilayers of unsonicated dispersions.

Bupranolol↗

PubMed1983

[Effect of preparation and storage on drug release from ointments containing the dissolved drug].

The drug release from an ointment that contains dissolved drug depends on the kind of preparation and on the time of storage. This indicates a relationship between shear treatment (disruption of the gel matrix) and liberation rate. With increasing storage time of the ointment the liberation rate decreases due to the increasing diffusional resistance of the reforming gel matrix.

Bupranolol↗